The protective role IL-37 during the development of experimental colitis has been demonstrated in IL-37 transgenic mice following DSS challenge, showing substantially reduced clinical signs and symptoms and histopathology severity from IL-37 overexpression transgenic mice, compared to that of wildtype counterparts (59). This evidence concerns the gene IL37 and colitis.